NSE · CONCORDBIO
Concord Biotech Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹312 Cr with net profit ₹76 Cr — a 24.24% net margin, versus 23.49% the period before.
Shareholding
As of 2026-11-30
- Promoter44.09%
- Public37.57%
- FII7.34%
- DII11.01%
91,337 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 3.27× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #26 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,51,075 Cr | 36.65 | 5.05 | 13.79% | 17.89% |
| Laurus Labs Limited | ₹1,30,972 Cr | 97.74 | 21.57 | 22.11% | 17.13% |
| Zydus Lifesciences Ltd. | ₹1,18,693 Cr | 26.12 | 4.27 | 15.1% | 14.11% |
| Dr Reddys Laboratories Ltd. | ₹1,15,267 Cr | 41.17 | 2.96 | 7.21% | 8.49% |
| Cipla Ltd. | ₹1,12,442 Cr | 36.21 | 3.18 | 8.18% | 10.39% |
| Mankind Pharma Limited | ₹1,09,044 Cr | 46.73 | 6.23 | 12.76% | 14.58% |
| Aurobindo Pharma Ltd. | ₹1,04,903 Cr | 25.85 | 2.67 | 10.13% | 10.88% |
| Lupin Limited | ₹90,558 Cr | 16.07 | 3.76 | 21.65% | 17.07% |
| Glenmark Pharmaceuticals Ltd. | ₹74,507 Cr | 36.78 | 6.65 | 18.07% | 9.22% |
| Alkem Laboratories Ltd. | ₹61,146 Cr | 28.2 | 4.11 | 13.91% | 13.23% |
| Concord Biotech Limited(this company) | ₹12,428 Cr | 43.64 | 5.99 | 13.61% | 24.13% |
AI analysis
AI-generated · google/gemini-2.5-flashConcord Biotech Limited has a market capitalization of Rs 13966 Cr. The company's revenue was Rs 1244.53 Cr with revenue growth of 18%. The profit margin is 24.73%.
Positives
- +The debt-to-equity ratio is 0, indicating the company is debt-free.
- +The company reported a profit margin of 24.73%.
- +Promoter holding remains stable at 44.08% as of June 30, 2026.
- +Revenue growth was 18%.
Negatives
- −No quarterly EPS figures have been disclosed since Dec 2024.
- −The number of shareholders decreased from 377572 in August 2023 to 83325 in June 2026.
Financial Performance
In the Mar 2025 annual period, Concord Biotech Limited reported a revenue of Rs 1244.53 Cr and a net profit of Rs 371.64 Cr. Quarterly revenue for Mar 2026 was Rs 326.08 Cr, with a net profit of Rs 88.79 Cr. Revenue grew by 18%.
Profitability & Returns
The company has a Return on Equity (ROE) of 12.94% and a Return on Capital Employed (ROCE) of 17.08%. The profit margin was 24.73%. Earnings per share (EPS) for the Mar 2025 annual period was Rs 35.52.
Balance Sheet
Concord Biotech Limited has a debt-to-equity ratio of 0, indicating no debt. The book value per share is Rs 192.81.
Ownership & Pledges
As of June 30, 2026, promoter holding stands at 44.08%. Public shareholding is 39.03%, while institutional holding is 16.88%. There are no promoter pledges reported.
Data as of — price: 2026-11-14 · financials: Sep 26 · shareholding: Nov 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.